Conference presentation


VASTox plc
30 April 2007

                                   VASTox plc

                          ("VASTox" or "the Company")



VASTOX TO PRESENT DATA FROM DUCHENNE MUSCULAR DYSTROPHY DRUG DISCOVERY PROGRAMME
                      AT LEADING INTERNATIONAL CONFERENCE



Oxford, UK, 30 April 2007 - VASTox plc (AIM: VOX), a leading UK biotechnology
company, announces that Professor Kay Davies, co-founder of VASTox and Chair of
the Company's Scientific Advisory Board, will be presenting at "The 20th
Anniversary of the DMD Gene Discovery: Impact on Muscle, Disease and Therapy"
conference, which will take place on 3-5 May 2007 in Ottawa, Canada.



This conference, which is being co-sponsored by VASTox, will bring together the
world's pre-eminent scientists in the field of musculoskeletal disease research
from commercial and academic backgrounds.  Prof. Davies, a leading expert in
Duchenne Muscular Dystrophy ("DMD"), will present data from VASTox's unique,
disease modifying approach for a DMD therapy at the conference.  Also in
attendance from VASTox will be the Company's Chief Scientific Officer, Richard
Storer, PhD and Director of Programmes, Jon Tinsley, PhD.



                                    - ends -



For more information please contact:

VASTox
Steven Lee, PhD, Chief Executive Officer                Tel: +44 (0)1235 443951
Richard Storer, PhD, Chief Scientific Officer

Citigate Dewe Rogerson
Mark Swallow / David Dible / Valerie Auffray            Tel: +44 (0)207 638 9571



About VASTox plc



VASTox is a leading UK biotechnology company that discovers and develops
proprietary new drugs. The Company's internal drug development programmes are
underpinned by its advanced chemistry and drug screening (chemical genomics)
technology platforms, which it also provides on a collaborative or
fee-for-service basis to the pharmaceutical industry.



VASTox has a broad range of drug discovery programmes in the clinical,
pre-clinical and discovery stages of development, which target serious diseases
with a high unmet medical need. These therapeutic areas include neuro-disorders
(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,
oncology and regenerative medicines.



VASTox's in-house drug development capabilities combine world-class expertise in
both medicinal and carbohydrate chemistry with high-volume, high-content
screening using its proprietary zebrafish and fruitfly technologies (chemical
genomics). These whole organism screens have the potential to dramatically
decrease the time and


cost of drug discovery and development by delivering data that are highly
predictive of the efficacy and toxicity of potential drug compounds in humans.



The company listed on the AIM market of the London Stock Exchange in October
2004 - symbol: VOX



Further information about the company is available at www.vastox.com



This document contains "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as "anticipates", "intends", "plans",
"seeks", "believes", "estimates", "expects" and similar references to future
periods, or by the inclusion of forecasts or projections.



Forward-looking statements are based on the Company's current expectations and
assumptions regarding our business, the economy and other future conditions.
Because forward-looking statements relate to the future, by their nature, they
are subject to inherent uncertainties, risks and changes in circumstances that
are difficult to predict. The Company's actual results may differ materially
from those contemplated by the forward-looking statements. The Company cautions
you therefore that you should not rely on any of these forward-looking
statements as statements of historical fact or as guarantees or assurances of
future performance. Important factors that could cause actual results to differ
materially from those in the forward-looking statements and regional, national,
global political, economic, business, competitive, market and regulatory
conditions.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NRASESFMWSWSEEL
Vox Valor Capital (LSE:VOX)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025